bioMérieux has acquired SpinChip Diagnostics ASA for €138 million to strengthen its position in point-of-care diagnostics, focusing on rapid immunoassays for acute care settings.

Target Overview

bioMérieux, a global leader in in vitro diagnostics, has announced its intent to acquire SpinChip Diagnostics ASA, a privately held Norwegian diagnostics company. SpinChip has created an innovative immunoassay diagnostics platform featuring a compact benchtop analyzer capable of delivering results from whole blood samples in just 10 minutes, matching the high sensitivity of traditional laboratory instruments. bioMérieux has been a minority stakeholder in SpinChip since March 2024, positioning it for deeper collaboration and investment.

SpinChip is particularly focused on developing laboratory-quality tests for conditions prevalent in acute care settings, notably Myocardial Infarction (MI), which remains a major cause of serious health complications and fatalities worldwide. Current diagnostic methods, although improved by high-sensitivity cardiac troponin assays, are often hindered by lengthy sample transportation and processing times, which can lead to extended stays in Emergency Departments and escalate overall healthcare costs due to diagnostic delays.

Industry Overview in Norway

The diagnostics industry in Norway is witnessing significant advancements, driven by innovation and technological advancements. With a strong emphasis on improving healthcare outcomes, investing in precision diagnostics, and enha